The research, led by Zhuo Han and Nan Wang of Tangdu Hospital at the Fourth Military Medical University together with colleagues from Beijing Chaoyang Hospital and Xijing Hospital, analyzed 154 patients with obstructive colorectal cancer treated between 2011 and 2025. Ninety-three patients received a self-expandable metal stent followed by neoadjuvant therapy, while 61 underwent stent placement alone before surgery. Because treatment practices evolved dramatically over the fourteen-year enrollment window, the investigators stratified their analysis into two eras, 2011 to 2020 and 2021 to 2025, to separate the effects of the combined strategy from the effects of technological progress.

The biological rationale behind the combined approach is rooted in the peculiar hostility of the obstructed bowel. Compared with non-obstructive colorectal cancer, obstructed tumors are more often left-sided, larger, more poorly differentiated, and diagnosed at more advanced stages, with a greater tendency toward peritoneal spread. Obstruction also drives a cascade of systemic problems: elevated inflammatory markers such as C-reactive protein and interleukin-6, hypoproteinemia and malnutrition, and reduced physical activity that accelerates muscle loss and frailty. Recent molecular work has even identified distinct features of the obstructed tumor microenvironment, including altered extracellular matrix stiffness, activated cancer-associated fibroblasts, and a dense infiltration of CD8-positive T cells that paradoxically correlates with worse prognosis.

Emergency surgery for these patients carries perioperative mortality rates as high as 10 to 15 percent, along with elevated risks of anastomotic leakage, wound infection, and permanent stoma formation. Self-expandable metal stents, introduced in the 1990s, offered a minimally invasive alternative: an endoscopist deploys a mesh tube across the tumor, restoring bowel continuity within hours and converting an emergency into an elective operation. Meta-analyses have shown lower early complication rates, lower mortality, and far fewer stomas with stenting compared with emergency surgery. Yet long-term oncological concerns persisted, most notably a prospective study reporting significantly higher local recurrence after stenting, possibly linked to microperforations or mechanical manipulation of the tumor releasing circulating tumor DNA.

The new study addresses those concerns by layering neoadjuvant therapy onto the stent pathway. After decompression, multidisciplinary teams at each center assessed patients for systemic treatment based on locally advanced disease, molecular subtype, resectability, and performance status. Regimens ranged from XELOX and FOLFOX chemotherapy to combinations with cetuximab for RAS and BRAF wild-type left-sided tumors, and immunotherapy for patients with microsatellite instability-high or mismatch repair-deficient tumors. The theory is that decompression first reduces bowel wall edema and peritumoral inflammation, creating a healthier substrate for treatment and surgery, while neoadjuvant drugs shrink the tumor, downstage nodal disease, and potentially eradicate micrometastases.

The short-term surgical results were striking. In the 2011 to 2020 cohort, the stent-plus-therapy group had an intraoperative stoma rate of 8.6 percent versus 29.0 percent for stent alone, and postoperative complications of 8.6 percent versus 29.0 percent, both statistically significant differences. These advantages persisted into the 2021 to 2025 period. The authors attribute this to a synergistic mechanism: stent-induced decompression resolves intestinal wall edema and restores blood supply, converting lesions once deemed unsuitable for safe anastomosis into ones where primary reconstruction is feasible, while neoadjuvant therapy further reduces tumor volume and inflammation. Avoiding a stoma carries profound quality-of-life implications, with longitudinal data showing that ostomy patients suffer persistent deficits in physical, emotional, and social functioning for up to a year after surgery.

Pathological outcomes told an equally compelling story about the modern era. In the 2021 to 2025 cohort, 20.7 percent of neoadjuvant-treated patients achieved major tumor regression, graded as Tumor Regression Grade 0 to 1, and rates of T and N downstaging reached 39.7 percent and 60.3 percent respectively, far exceeding the earlier period when regimens consisted mainly of standard chemotherapy alone. The contemporary group also showed significantly fewer positive lymph nodes and significant improvements in pathological T and N stages. The authors link this enhanced response to the evolution of neoadjuvant regimens, including targeted and immune-based combinations that act on both the primary tumor and micrometastatic disease.

Survival analysis revealed a nuanced picture. In the earlier cohort, the neoadjuvant group showed marginally better three- and five-year disease-free and overall survival, but the differences did not reach statistical significance. In the 2021 to 2025 cohort, however, the combined strategy was associated with a statistically significant improvement in overall survival, with a reported P value of 0.013, while disease-free survival had not yet diverged, possibly because follow-up in that cohort remains short at a median of 41.3 months. The authors caution that retrospective design, modest sample size, and the absence of propensity score matching limit causal inference, but the consistency of surgical and pathological benefits across both eras strengthens the overall signal.

Perhaps the most practice-changing finding concerns timing. For patients treated with a stent alone, an interval of 14 to 21 days between stenting and surgery was associated with significantly better overall survival, a window during which decompression restores nutrition, dampens systemic inflammation, and allows prehabilitation without giving the tumor unnecessary time to progress. For patients receiving neoadjuvant therapy, the calculus differs: intervals exceeding 90 days were associated with significantly worse disease-free survival, suggesting that systemic treatment should be completed and surgery performed within roughly three months. A nationwide Chinese survey cited in the paper found that nearly half of stenting hospitals operated within two weeks, while about a fifth waited ten to twelve weeks when neoadjuvant therapy was given, underscoring how variable current practice remains.

The study arrives as two prospective trials, OUTSTAND and NACSOC-02, work to confirm whether stent-based neoadjuvant strategies can be standardized for obstructive left-sided colorectal cancer, with the latter testing immunotherapy combinations after decompression. For now, the retrospective evidence offers a coherent clinical algorithm: decompress with a stent at an experienced center, use the restored physiological window to deliver modern systemic therapy tailored to molecular subtype, and schedule radical surgery within a defined interval, ideally before 90 days elapse. If prospective data validate these findings, the dreaded obstructed bowel, long a surgical emergency defined by rushed decisions and permanent stomas, may instead become the starting point of a carefully sequenced, multidisciplinary treatment plan that improves both survival and the daily lives of patients.

Subject of Research: Neoadjuvant therapy combined with self-expandable metal stent placement for obstructive colorectal cancer

Article Title: Comparative effectiveness of neoadjuvant therapy combined with stent placement versus stent alone in obstructive colorectal cancer: a multicenter retrospective analysis

Article References: Han, Z., Zhang, B., Liu, S., Wu, T., Qiao, Q., He, X., Han, J., & Wang, N. (2026). Comparative effectiveness of neoadjuvant therapy combined with stent placement versus stent alone in obstructive colorectal cancer: a multicenter retrospective analysis. BMC Cancer, 26(1), Article 1139. https://doi.org/10.1186/s12885-026-16728-2

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16728-2

Keywords: colorectal cancer, bowel obstruction, self-expandable metal stent, neoadjuvant therapy, bridge to surgery, overall survival, disease-free survival, tumor regression grade, surgical timing, stoma, immunotherapy, retrospective study

Small bowel obstruction is far from a niche problem. Postoperative adhesions account for an estimated 12 to 16 percent of surgical admissions in the United States, and comparable burdens have been documented in Swedish and Korean registry data. Management is frequently prolonged, may require reoperation or extensive bowel resection, and carries an operative mortality approaching 5 percent, alongside impaired nutrition and reduced quality of life for survivors. Despite this clinical and economic toll, standardized prevention strategies remain elusive, and current practice depends largely on surgeon preference rather than high-quality evidence.

The biological logic behind the new findings is straightforward. Postoperative obstruction arises primarily when the parietal and visceral peritoneum, the slippery membranes lining the abdominal cavity and covering the organs, are damaged during surgery, prompting scar tissue formation. Laparoscopic surgery, performed through small incisions with camera guidance, minimizes peritoneal trauma. Adhesion prevention materials, such as the hyaluronic acid-carboxymethylcellulose film Seprafilm, act as physical barriers between injured peritoneal surfaces during healing. Yet randomized trials, including the influential COLOR II trial of rectal cancer, had failed to show that laparoscopy significantly reduces obstruction, partly because laparoscopy reduces parietal adhesions more effectively than visceral ones.

To resolve these uncertainties, the researchers drew on a nationwide retrospective survey covering 18,798 gastrointestinal surgeries across 32 institutions, of which 5811 involved colorectal disease. After excluding benign conditions and incomplete records, 5458 patients with histologically confirmed colorectal cancer remained. Of these, 3193 patients, or 58.5 percent, underwent laparoscopic surgery, while 2265, or 41.5 percent, had open operations. Over five years of follow-up, 283 cases of small bowel obstruction were identified, defined as clinically diagnosed obstruction requiring hospitalization and fasting for more than one day, with suspected cancer recurrences excluded.

Because patients were treated at many different hospitals, the team used mixed-effects logistic regression with hospital as a random intercept, a statistical technique that accounts for institutional clustering and prevents any single center from distorting the results. The model adjusted for age, sex, tumor location, and stoma creation. The headline result was striking: laparoscopic surgery was independently associated with a 42 percent reduction in the odds of developing obstruction compared with open surgery, with an adjusted odds ratio of 0.58 and a confidence interval of 0.45 to 0.74, highly statistically significant. In absolute terms, the risk fell from 6.8 percent with open surgery to 4.1 percent with laparoscopy, an absolute risk reduction of 2.7 percent, equivalent to a number needed to treat of 37.

That last figure deserves unpacking for readers unfamiliar with clinical epidemiology. A number needed to treat of 37 means that for every 37 patients shifted from open to laparoscopic surgery, one case of small bowel obstruction would be prevented over five years. The benefit, however, was not uniform across the bowel. Site-specific analyses revealed statistically significant reductions in ascending colon surgery, where the number needed to treat dropped to 22.2, and in sigmoid colon surgery, at 30.2. No significant reduction was seen in the cecum, transverse colon, descending colon, or rectum. The transverse colon, highly mobile and often requiring omental dissection, may blunt laparoscopy’s advantage, while rectal surgery involves deep pelvic dissection, frequent stomas, and possible neoadjuvant radiotherapy, all of which complicate the picture.

In contrast to the laparoscopy findings, adhesion prevention materials were a clear null result. Seprafilm, the only such product approved for gastrointestinal surgery in Japan during the study period, showed no significant association with reduced obstruction, with an adjusted odds ratio of 1.01 and a p-value of 0.94. When patients were stratified by surgical approach, obstruction rates were nearly identical with and without the film in both laparoscopic and open groups. Usage varied dramatically across hospitals, from 0 to 99.2 percent, and surgeons applied it at their own discretion, raising the possibility of confounding by indication, in which the film was preferentially used in the most complex, highest-risk operations, potentially masking a genuine benefit. Still, the findings echo a randomized trial that likewise found no significant obstruction reduction with the material in colorectal cancer patients.

Perhaps the most clinically provocative finding concerned stomas. Patients who received a stoma, a surgical opening of the bowel through the abdominal wall, faced an 84 percent increase in the odds of obstruction, with an odds ratio of 1.84. Among rectal cancer patients, 11.4 percent of those with stomas developed obstruction versus 5.1 percent of those without. Notably, the risk was similar for ileostomies, at 13.2 percent, and colostomies, at 10.6 percent, suggesting that the presence of a stoma itself, rather than its type or fluid output, is the key driver. The mechanism likely involves both additional peritoneal trauma from stoma creation and closure and non-adhesive problems such as kinking at the abdominal wall passage or parastomal hernia. The authors argue that stoma creation warrants judicious use, reserved for cases where the danger of anastomotic leakage clearly outweighs the obstruction risk.

Tumor location emerged as an independent determinant in its own right. Rectal cancer carried the highest obstruction incidence at 6.8 percent, and all colonic sites except the descending colon showed significantly lower odds than the rectum. This pattern reflects surgical anatomy: total mesorectal excision in the confined pelvic space, often combined with radiotherapy and stomas, promotes adhesion formation, while descending colon resections demand splenic flexure mobilization and extended dissection. Sigmoid colon surgery, despite its anatomical proximity to the rectum, enjoyed lower risk, plausibly because of more straightforward operative planes and fewer stomas.

The study’s statistical rigor extended to sensitivity analyses. E-value calculations, which estimate how strong an unmeasured confounder would need to be to erase the observed associations, reached 2.84 for laparoscopic surgery and 3.08 for stoma creation, indicating reasonably robust findings, while the E-value of 1.11 for adhesion films was consistent with a true null effect. Nonetheless, the authors are candid about limitations. The retrospective, non-randomized design cannot prove causation, and variables such as body mass index, tumor stage, diabetes, neoadjuvant therapy, prior abdominal surgery, and emergency operations were unavailable. Because factors like advanced stage and obesity push surgeons toward open surgery while independently raising adhesion risk, confounding, if present, would tend to overstate laparoscopy’s protective effect, not undermine it. The binary five-year endpoint also prevented time-to-event analysis, could not distinguish early from late obstruction, and did not capture obstruction severity or episodes occurring decades later.

Even with those caveats, the study’s implications are substantial. It suggests that the benefits of minimally invasive colorectal cancer surgery extend beyond the well-established short-term advantages of less pain and faster recovery into meaningful long-term protection against bowel obstruction, particularly in ascending and sigmoid colon resections. It casts serious doubt on the routine use of adhesion barrier films under current, unstandardized practice patterns, and it flags stoma creation as a modifiable risk factor deserving careful weighing. As robotic platforms, refined laparoscopic techniques, and enhanced recovery protocols spread, the balance of risks may shift further, and the authors call for prospective studies with time-to-event data reflecting contemporary practice. For now, the message to surgical teams is clear: the route taken through the abdominal wall may echo in a patient’s health for years to come.

Subject of Research: The association of laparoscopic surgery, adhesion prevention materials, and stoma creation with five-year small bowel obstruction risk after colorectal cancer surgery.

Article Title: Laparoscopic Surgery Is Associated With Reduced Small Bowel Obstruction Risk After Colorectal Cancer Surgery: A Nationwide Cohort Study of 5458 Patients

Article References: Yamada, T., Fujita, F., Eto, K., Kataoka, K., Yukawa, N., Sugimoto, K., Shimoyama, R., Fukazawa, A., Kumamoto, K., Takayama, Y., Komono, A., Matsuda, A., Ohta, R., Sonoda, H., Okuya, K., Ihara, K., Yokoyama, Y., Nishino, T., Akiyama, Y., & Ichikawa, D. (2026). Laparoscopic Surgery Is Associated With Reduced Small Bowel Obstruction Risk After Colorectal Cancer Surgery: A Nationwide Cohort Study of 5458 Patients. Annals of Gastroenterological Surgery, Article ags3.70280. https://doi.org/10.1002/ags3.70280

Image Credits: AI Generated

DOI: 10.1002/ags3.70280

Keywords: colorectal cancer, laparoscopic surgery, small bowel obstruction, adhesions, adhesion prevention materials, stoma, open surgery, nationwide cohort study, surgical outcomes, Seprafilm, rectal cancer, postoperative complications